Carisoprodol: Update on abuse potential and legal status

Southern Medical Journal

Volumn 105, Issue 11, 2012, Pages 619-623

  Reeves, Roy R ^a   Burke, Randy S ^a   Kose, Samet ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

carisoprodol; controlled substances; substance abuse

Indexed keywords

4 AMINOBUTYRIC ACID; CARISOPRODOL; FLUMAZENIL; LORAZEPAM; MEPROBAMATE; MIO RELAX; OLANZAPINE; RELACTON C; RELAXIBYS; SCUTAMIL C; SOMACID; SONOMA; SORIDOL; UNCLASSIFIED DRUG;

ANXIETY; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG INTOXICATION; DRUG MISUSE; HUMAN; INSOMNIA; MEDICOLEGAL ASPECT; MUSCLE RELAXATION; MUSCLE TWITCH; MUSCULOSKELETAL PAIN; PARANOIA; PRESCRIPTION; RECOMMENDED DRUG DOSE; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; TRAFFIC ACCIDENT; TREMOR; UNITED STATES; VISUAL HALLUCINATION; WITHDRAWAL SYNDROME;

CARISOPRODOL; CONTROLLED SUBSTANCES; DRUG AND NARCOTIC CONTROL; EUROPE; HUMANS; MUSCLE RELAXANTS, CENTRAL; MUSCULOSKELETAL PAIN; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84869395235     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31826f5310     Document Type: Review

References (50)

1. Littrell RA, Hayes LR, Stillner V. Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J 1993;86:753-756.
2. Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther 2004;26:1355-1367.
3. Rho JM, Donevan SD, Rogawski MA. Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther 1997;280:1383-1391.
4. Ewing JA, Fullilove RE. Addiction to meprobamate. N Engl J Med 1957;257:76-77.
5. Gonzalez LA, Gatch MB, Forster MJ, et al. Abuse potential of Soma: the GABA(A) receptor as a target. Mol Cell Pharmacol 2009;1:180-186.
6. Fass JA. Carisoprodol legal status and patterns of abuse. Ann Pharmacother 2010; 44:1962-1967.
7. Morse RM, Chua L. Carisoprodol dependence: a case report. Am J Drug Alcohol Abuse 1978;5:527-530.
8. Luehr JG,Meyerle KA, LarsonEW.Mail-order (veterinary) drug dependence. JAMA 1990;263:657.
9. Elder NC. Abuse of skeletal muscle relaxants. Am Fam Physician 1991;44: 1223-1226.
10. Rust GS, Hatch R, Gums JG. Carisoprodol as a drug of abuse. Arch Fam Med 1993;429-432.
11. Sikdar S, Basu D, Malhotra AK, et al. Carisoprodol abuse: a report from India. Acta Psychiatr Scand 1993;88:302-303.
12. Dougherty RJ. Carisoprodol should be a controlled substance. Arch Fam Med 1995;4:582.
13. Heacock C, Bauer MS. Tolerance and dependence risk with the use of carisoprodol. Am Fam Physician 2004;69:1622-1623.
14. Reeves RR, Mack JE. Possible dangerous interaction of oxycontin and carisoprodol. Am Fam Physician 2003;67:941-942.
15. Littrell RA, Sage T, Miller W. Meprobamate dependence secondary to carisoprodol (Soma) use. Am J Drug Alcohol Abuse 1993;19:133-134.
16. Reeves RR, Pinkofsky HB, Carter OS. Carisoprodol: a drug of continuing abuse. J Am Osteopath Assoc 1997;97:723-724.
17. Reeves RR, Carter OS, Pinkofsky HB. Use of carisoprodol by substance abusers to modify the effects of illicit drugs. South Med J 1999;92:441.
18. Reeves RR, Liberto V. Abuse of combinations of carisoprodol and tramadol. South Med J 2001;94:512-514.
19. Reeves RR, Henderson RH, LadnerMD. Carisoprodol abuse inMississippi. J Miss State Med Assoc 2007;363-365.
20. Reeves RR, Burke RS. Carisoprodol: abuse potential and withdrawal syndrome. Curr Drug Abuse Reviews 2010;3:33-38.
21. Reeves RR, Carter OS, Pinkofsky HB, et al. Carisoprodol (soma): abuse potential and physician unawareness. J Addict Dis 1999;18:51-56.
22. Owens C, Pugmire B, Salness T, et al. Abuse potential of carisoprodol: a retrospective reviewof Idaho Medicaid pharmacy and medical claims data. Clin Ther 2007;29:2222-2225.
23. Wyller TB, Korsmo G, Gadeholt G. Dependence on carisoprodol (Somadril)? A prospective study among prisoners. Tidsskr Nor Laegeforen 1991;111: 193-195.
24. Reeves RR, Parker JD. Somatic dysfunction during carisoprodolwithdrawal syndrome. J Am Osteopath Assoc 2003;103:75-80.
25. Reeves RR, Beddingfield JJ, Mack JE. Carisoprodol withdrawal syndrome. Pharmacotherapy 2004;24:1804-1806.
26. Rohatgi G, Rissmiller DJ, Gorman JM. Treatment of carisoprodol dependence: a case report. J Psychiatr Pract 2005;11:347-352.
27. Reeves RR, Hammer JS, Pendarvis RO. Is the frequency of carisoprodol withdrawal syndrome increasing? Pharmacotherapy 2007;27:1462-1466.
28. Eleid MF, Krahn LE, Agrwal N, et al. Carisoprodol withdrawal after internet purchase. Neurologist 2010;16:262-264.
29. Roberge RJ, Lin E, Krenzelok EP. Flumazenil reversal of carisoprodol (Soma) intoxication. J Emerg Med 2000;18:61-64.
30. Swinyard EA, Chin L, Fingl E. Withdrawal hyperexcitability following chronic administration of meprobamate to mice. Science 1957;125: 739-741.
31. Gatch MB, Nguyen JD, Carbonaro T, et al. Carisoprodol tolerance and precipitated withdrawal. Drug Alcohol Depend 2012;123:29-34.
32. Logan BK, Case GA, Gordon AM. Carisoprodol, meprobamate, and driving impairment. J Forensic Sci 2000;45:619-623.
33. Bramness JG, Skurtveit S, Morland J. Impairment due to intake of carisoprodol. Drug Alcohol Depend 2004;74:311-318.
34. Hoiseth G, Karinen R, Sorlid HK, et al. The effect of scheduling and withdrawal of carisoprodol on the prevalence of intoxications with the drug. Basic Clin Pharmacol Toxicol 2009;105:345-349.
35. Zacny JP, Paice JA, Coalson DW. Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers. Pharmacol Biochem Behav 2011;100:138-143.
36. Zacny JP, Paice JA, Coalson DW. Subjective and psychomotor effects of carisoprodol in combination with oxycodone in healthy volunteers. Drug Alcohol Depend 2012;120:229-232.
37. Department of Health and Human Services. Emergency department trends from the Drug Abuse Warning Network, final estimates 1994-2001. http://www.oas. samhsa.gov/DAWN/Final2k1EDtrends/text/EDtrend 2001v6.pdf. Published August 2002. Accessed December 12, 2011.
38. Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network. National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 11-4659, DAWN Ser D-35. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.
39. Office of Applied Studies, Substance Abuse and Mental Health Services. National survey on drug use and health. www.oas.samhsa.gov/nsduh.htm. Accessed December 12, 2011.
40. Bronstein AC, Spyker DA, Cantilena LR, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th annual report. Clin Toxicol (Phila) 2009;47: 911-1084.
41. Ukens C. Carisoprodol abuse on rise, warns Mississippi board. Drug Topics 1992;19:13.
42. Davis GG, Alexander CB. A review of carisoprodol deaths in Jefferson County, Alabama. South Med J 1998;91:726-730.
43. Forrester MB. Carisoprodol abuse in Texas, 1998-2003. J Med Toxicol 2006;2:8-13.
44. Bramness JG, Furu K, Engeland A, et al. Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. Br J Clin Pharmacol 2007;64:210-218.
45. European Medicines Agency. Questions and answers on the recommendation to suspend the marketing authorizations for carisoprodolcontaining medicines. Doc. ref. EMEA/520140/2007, November 15, 2007.
46. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorizations for carisoprodol-containing medicinal products. Doc. ref. EMEA/520463/2007, November 16, 2007.
47. Tennessee Board of Pharmacy. Tramadol and carisoprodol now classified schedule IV. Tennessee Board Pharm News 2011;13:1.
48. Wyoming Board of Pharmacy. Tramadol and carisoprodol to become Schedule IV inWyoming. Wyoming State Board Pharm Newsl 2011;20:1.
49. Mississippi Board of Pharmacy. Annual controlled substance inventory. Mississippi Board Pharm Newsl May 2011.
50. Drug Enforcement Administration. Schedule of controlled substances: placement of carisoprodol into Schedule IV. Fed Reg 2011;76: 77330-77360.